FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048751726> ?p ?o ?g. }

• W3048751726 endingPage "1463" @default.
• W3048751726 startingPage "1462.3" @default.
• W3048751726 abstract "Objectives: To evaluate the efficacy of tofacitinib therapy (TOFA) in biologic naive and had prior biologic use history patients with rheumatoid arthritis (RA) according to OREL register Methods: Were analyzed the data from Russian national register of patients with RA - OREL treated with TOFA. 138 patients (118 woman, Me;IQR age 55.0 (43.0-63.0) years, disease duration 128.0 (84.0-213.0) months, mean DAS 28 5.5 (4.6-6.2), SDAI 30.5 (21.4-42.9), positive for ACCP (73%)/RF (77%), who were non-responders to MTX at least 15 mg/week and/or other synthetic DMARDs) who received TOFA therapy for more than 1 year were selected for statistical analysis. TOFA used in 26 (18.8%) pts without DMARDs, combination with MTX in 82 (59.4%) pts, leflunomide in 21 (15.2%). Low-dose oral corticosteroids (<10 mg/day prednisone or equivalent) were received by 43 (31.2%) pts. TOFA therapy was started in all pts in dose 5 mg BID per os with dose escalation to 10 mg BID in (86%) pts. Results: The use of TOFA was accompanied by a decrease in the disease activity and the level of acute phase reactants (CRP and ESR) after 12, 24 and 48 weeks of therapy, p<0.05, table 1. Depending on the previous treatment with biological DMARDs, all patients were divided into two groups: had prior biologic use history pts (group 1) (n=51) and biologic naïve pts (group 2) (n=87), table 1. Table 1. Baseline vs month 1 Parameters Weeks All patients (n=138) Had prior biologic use history (group 1) (n=51) Biologic naive (group 2) (n=87) DAS28 baseline 5,5 (4,6-6,2) 5,1 (4,5-5,9) 5,7 (4,8-6,5)$ week 12 4,2 (3,1-4,8)* 3,9 (2,8-4,8)* 4,4 (3,7-4,8)* week 24 3,4 (2,7-4,4)* 3,5 (2,4-4,3)* 3,4 (2,8-4,5)* week 48 3,3 (2,5-4,4)* 3,2 (2,4-4,2)* 3,4 (2,7-4,4)* SDAI baseline 30,5 (21,4-42,9) 28,6 (18,1-36,6) 33,1 (22,6-45,9) week 12 14,5 (7,1-23,3)* 13,1 (5,1-19,1)* 16,3 (9,3-25,6)* week 24 10,5 (5,1-19,0)* 11,0 (5,5-17,6)* 9,1 (4,7-20,4)* week 48 10,3 (4,9-17,7)* 10,2 (3,4-15,8)* 10,9 (6,2-18,1)* CDAI baseline 28,2 (20,0-37,1) 25,7 (17,0-33,7) 30,0 (21,5-40,5) week 12 14,9 (8,0-22,5)* 13,0 (6,8-18,7)* 16,6 (9,0-24,0)* week 24 10,0 (5,0-18,0)* 11,0 (4,7-16,0)* 9,3 (5,0-18,0)* week 48 10,1 (5,8-17,0)* 10,4 (4,0-16,0)* 10,0 (6,0-17,0)* CRP, mg/l baseline 15,6 (6,5-38,0) 15,6 (6,0-38,1) 15,4 (6,9-36,7) week 12 5,5 (1,7-12,1)* 6,4 (2,7-10,4)* 5,2 (1,3-12,8)* week 24 4,5 (1,0-10,0)* 5,0 (0,8-9,8)* 4,2 (1,0-10,0)* week 48 4,0 (0,7-9,0)* 2,9 (0,6-9,6)* 4,0 (0,8-8,9)* ESR, mm/h baseline 32,0 (23,0-48,0) 29,0 (16,0-37,0) 32,0 (23,0-49,0)$ week 12 21,0 (17,0-33,0)* 20,0 (12,0-33,0) 21,0 (17,0-33,0)* week 24 21,0 (12,0-31,0)* 13,0 (9,0-28,0) 21,0 (12,0-31,0)* week 48 16,0 (10,0-27,0)* 16,0 (7,0-30,0)* 16,0 (10,0-27,0)* *p<0.05 from baseline; $p<0.05 between the groups 1 and 2 Patients of the second group had a higher disease activity and ESR before therapy. The use of TOFA was accompanied by a decrease in the disease activity and the level of acute phase reactants (CRP and ESR) in both groups of patients. By week 48 of treatment, no significant difference between the groups according to the disease activity was detected. In the first and the second group of pts on the 48-th week of therapy remission/low disease activity was achieved on DAS 28 in 51% and 43% (р=0.57), high disease activity on DAS 28 in 12% and 8% (p=0.48). Conclusion: An analysis of the data from the Russian national register of patients with RA demonstrated similar efficacy of TOFA among patients who received and did not receive previous biological therapy. Disclosure of Interests: Evgeny Nasonov Speakers bureau: Lilly, AbbVie, Pfizer, Biocad, R-Pharm, Anastasia Avdeeva: None declared, Anna Misiyuk: None declared, Azamat Satybaldyev: None declared, Valentina Sorotskaya: None declared, Oxana Fomina: None declared, Aida Babaeva: None declared, N Lapkina: None declared, Alexander Lila: None declared" @default.
• W3048751726 created "2020-08-18" @default.
• W3048751726 creator A5000519299 @default.
• W3048751726 creator A5000913174 @default.
• W3048751726 creator A5001854360 @default.
• W3048751726 creator A5002921268 @default.
• W3048751726 creator A5002976325 @default.
• W3048751726 creator A5033103146 @default.
• W3048751726 creator A5060084797 @default.
• W3048751726 creator A5065687280 @default.
• W3048751726 creator A5069106726 @default.
• W3048751726 date "2020-06-01" @default.
• W3048751726 modified "2023-10-14" @default.
• W3048751726 title "AB0328 SIMILAR EFFICACY OF TOFACITINIB THERAPY IN BIOLOGIC NAIVE AND HAD PRIOR BIOLOGIC USE HISTORY PATIENTS WITH RHEUMATOID ARTHRITIS (OREL REGISTER)" @default.
• W3048751726 doi "https://doi.org/10.1136/annrheumdis-2020-eular.3052" @default.
• W3048751726 hasPublicationYear "2020" @default.
• W3048751726 type Work @default.
• W3048751726 sameAs 3048751726 @default.
• W3048751726 citedByCount "0" @default.
• W3048751726 crossrefType "journal-article" @default.
• W3048751726 hasAuthorship W3048751726A5000519299 @default.
• W3048751726 hasAuthorship W3048751726A5000913174 @default.
• W3048751726 hasAuthorship W3048751726A5001854360 @default.
• W3048751726 hasAuthorship W3048751726A5002921268 @default.
• W3048751726 hasAuthorship W3048751726A5002976325 @default.
• W3048751726 hasAuthorship W3048751726A5033103146 @default.
• W3048751726 hasAuthorship W3048751726A5060084797 @default.
• W3048751726 hasAuthorship W3048751726A5065687280 @default.
• W3048751726 hasAuthorship W3048751726A5069106726 @default.
• W3048751726 hasBestOaLocation W30487517261 @default.
• W3048751726 hasConcept C126322002 @default.
• W3048751726 hasConcept C141071460 @default.
• W3048751726 hasConcept C2775905006 @default.
• W3048751726 hasConcept C2777575956 @default.
• W3048751726 hasConcept C2778715236 @default.
• W3048751726 hasConcept C2778720950 @default.
• W3048751726 hasConcept C2778886723 @default.
• W3048751726 hasConcept C71924100 @default.
• W3048751726 hasConcept C90924648 @default.
• W3048751726 hasConceptScore W3048751726C126322002 @default.
• W3048751726 hasConceptScore W3048751726C141071460 @default.
• W3048751726 hasConceptScore W3048751726C2775905006 @default.
• W3048751726 hasConceptScore W3048751726C2777575956 @default.
• W3048751726 hasConceptScore W3048751726C2778715236 @default.
• W3048751726 hasConceptScore W3048751726C2778720950 @default.
• W3048751726 hasConceptScore W3048751726C2778886723 @default.
• W3048751726 hasConceptScore W3048751726C71924100 @default.
• W3048751726 hasConceptScore W3048751726C90924648 @default.
• W3048751726 hasIssue "Suppl 1" @default.
• W3048751726 hasLocation W30487517261 @default.
• W3048751726 hasOpenAccess W3048751726 @default.
• W3048751726 hasPrimaryLocation W30487517261 @default.
• W3048751726 hasRelatedWork W2023666700 @default.
• W3048751726 hasRelatedWork W2037882730 @default.
• W3048751726 hasRelatedWork W2354775388 @default.
• W3048751726 hasRelatedWork W2368117966 @default.
• W3048751726 hasRelatedWork W2388245966 @default.
• W3048751726 hasRelatedWork W2755978387 @default.
• W3048751726 hasRelatedWork W2887641776 @default.
• W3048751726 hasRelatedWork W2981478968 @default.
• W3048751726 hasRelatedWork W3023801138 @default.
• W3048751726 hasRelatedWork W4225292413 @default.
• W3048751726 hasVolume "79" @default.
• W3048751726 isParatext "false" @default.
• W3048751726 isRetracted "false" @default.
• W3048751726 magId "3048751726" @default.
• W3048751726 workType "article" @default.